513000 | PD 98059 - CAS 167869-21-8 - Calbiochem

513000
Le prix n'a pas pu être récupéré
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitée Disponibilité limitée
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
      Nous vous tiendrons informé
      Voir les Prix & la Disponibilité
         ComparerClick To Print This Page

      Overview

      Tableau de caractéristiques principal

      Formule empirique Nº CAS

      Prix & Disponibilité

      RéférenceDisponibilité Conditionnement Qté Prix Quantité
      513000-10MG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitée Disponibilité limitée
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
          Nous vous tiendrons informé

          10 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          513000-25MG
          Récupération des données relatives à la disponibilité...
          Disponibilité limitée Disponibilité limitée
          Interrompu(e)
          Disponible en quantités limitées
          Disponibilité à confirmer
              Nous vous tiendrons informé

              25 mg
              Prix en cours de récupération
              Le prix n'a pas pu être récupéré
              À la validation de la commande Plus d'informations
              Vous avez sauvegardé ()
               
              Demander le prix
              513000-5MG
              Récupération des données relatives à la disponibilité...
              Disponibilité limitée Disponibilité limitée
              Interrompu(e)
              Disponible en quantités limitées
              Disponibilité à confirmer
                  Nous vous tiendrons informé

                  5 mg
                  Prix en cours de récupération
                  Le prix n'a pas pu être récupéré
                  À la validation de la commande Plus d'informations
                  Vous avez sauvegardé ()
                   
                  Demander le prix
                  Description
                  Aperçu Selective, reversible, and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates. Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase in MAP kinase activity produced by nerve growth factor (NGF; IC50 = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the p140trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Blocks LPS-induced activation of TNF-α gene expression. Inhibits cell growth and reverses the phenotype of ras-transformed BALB3T3 mouse fibroblasts and rat kidney cells. A 5 mg/ml solution of PD 98059 (Cat. No. 513001) in anhydrous DMSO is also available.
                  Référence 513000
                  Famille de marques Calbiochem®
                  Synonymes 2ʹ-Amino-3ʹ-methoxyflavone, MEK Inhibitor V
                  Références bibliographiques
                  Références bibliographiques Means, T.K., et al. 2000. J. Leukoc. Biol. 67, 885.
                  Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
                  Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
                  Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
                  Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
                  Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.
                  Informations produit
                  Numéro CAS 167869-21-8
                  ATP concurrente N
                  Forme Pale yellow solid
                  Formule de Hill C₁₆H₁₃NO₃
                  Formule chimique C₁₆H₁₃NO₃
                  Molar Mass 267.3
                  Réversible Y
                  Image de la formule structurale
                  Applications
                  Informations biologiques
                  Cible primaire MAP kinase kinase (MEK)
                  Cible primaire IC50 2 µM against NGF-induced increase in MAP kinase activity
                  Pureté ≥98% by HPLC
                  Informations physico-chimiques
                  Perméable aux cellules Y
                  Solubilité DMSO or MeOH
                  Dimensions
                  Informations sur les matériaux
                  Informations toxicologiques
                  Informations de sécurité selon le SGH
                  Informations sur la sécurité
                  Notifications sur l'utilisation du produit
                  Informations relatives au stockage et à l'expédition
                  Code Expé Ambient Temperature Only
                  Toxicité Standard Handling
                  Stockage -20°C
                  Protéger de la lumière Protect from light
                  Ne pas congeler No
                  Instructions spéciales Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
                  Informations sur l'emballage
                  Informations sur le transport
                  Information complémentaire
                  Caractéristiques

                  Documentation

                  FDS

                  Langues
                  Danmark Deutschland Ellas
                  English España France
                  Italia Korea Magyarország
                  Nederland  Norge Polska
                  Portugal Suomi Sverige
                  България

                  Certificats d'analyse

                  TitreNuméro de lot
                  513000

                  Références bibliographiques

                  Aperçu de la référence bibliographique
                  Means, T.K., et al. 2000. J. Leukoc. Biol. 67, 885.
                  Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
                  Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
                  Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
                  Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
                  Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.

                  Citations

                  Titre
                • Joao B. Oliveira, et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Procedings of the National Academy of Science 104, 8953-8958.
                • Alexandra Thiel, Mira Heinonen, Johanna Rintahaka, Tuija Hallikainen, and Annabrita Hemmes, Dan A. Dixon, Caj Haglund, and Ari Ristimaki. (2006) EXPRESSION OF CYCLOOXYGENASE-2 IS REGULATED BY GSK-3 IN GASTRIC CANCER CELLS. Journal of Biological Chemistry in press,.
                • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
                • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
                • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
                • Diane Gesty-Palmer, et al. (2005) b-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. Journal of Biological Chemistry 280, 32157-32167.
                • Renee M. Marshall, et al. (2005) Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. Journal of Immunology 175, 6402-6411.
                • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
                • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
                • Yona Goldshmit, et al. (2004) SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry 279, 16349-16355.
                • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
                • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
                • Michael J. Cross, et al. (2002) The Shb Adaptor Protein Binds to Tyrosine 766 in the FGFR-1 and Regulates the Ras/MEK/MAPK Pathway via FRS2 Phosphorylation in Endothelial Cells. Molecular Biology of the Cell 13, 2881-2893.
                • Maryse Delehedde, et al. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochemistry Journal 366, 235-244.
                • Silja Wessler, et al. (2000) Helicobacter pylori activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors. Journal of Biological Chemistry 275, 3629-3636.
                • Fiche technique

                  Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

                  Révision 21-January-2014 JSW
                  Synonymes 2ʹ-Amino-3ʹ-methoxyflavone, MEK Inhibitor V
                  Description Selective, reversible, and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates (noncompetitive with respect to ATP). Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase of MAP kinase activity produced by nerve growth factor (NGF; IC50 = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the pp140trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Inhibits cell growth and reverses the phenotype of ras-transformed BALB 3T3 mouse fibroblasts and rat kidney cells.
                  Forme Pale yellow solid
                  Numéro CAS 167869-21-8
                  Masse molaire 267.3
                  Formule chimique C₁₆H₁₃NO₃
                  Formule structurale
                  Pureté ≥98% by HPLC
                  Solubilité DMSO (20 mg/ml) or Methanol (0.7 mg/ml)
                  Stockage -20°C
                  Protect from light
                  Do Not Freeze No
                  Special Instructions Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 4 months at -20°C.
                  Toxicité Standard Handling
                  Références bibliographiques Means, T.K., et al. 2000. J. Leukoc. Biol. 67, 885.
                  Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
                  Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
                  Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
                  Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
                  Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.
                  Citation
                • Joao B. Oliveira, et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Procedings of the National Academy of Science 104, 8953-8958.
                • Alexandra Thiel, Mira Heinonen, Johanna Rintahaka, Tuija Hallikainen, and Annabrita Hemmes, Dan A. Dixon, Caj Haglund, and Ari Ristimaki. (2006) EXPRESSION OF CYCLOOXYGENASE-2 IS REGULATED BY GSK-3 IN GASTRIC CANCER CELLS. Journal of Biological Chemistry in press,.
                • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
                • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
                • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
                • Diane Gesty-Palmer, et al. (2005) b-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. Journal of Biological Chemistry 280, 32157-32167.
                • Renee M. Marshall, et al. (2005) Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. Journal of Immunology 175, 6402-6411.
                • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
                • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
                • Yona Goldshmit, et al. (2004) SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry 279, 16349-16355.
                • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
                • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
                • Michael J. Cross, et al. (2002) The Shb Adaptor Protein Binds to Tyrosine 766 in the FGFR-1 and Regulates the Ras/MEK/MAPK Pathway via FRS2 Phosphorylation in Endothelial Cells. Molecular Biology of the Cell 13, 2881-2893.
                • Maryse Delehedde, et al. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochemistry Journal 366, 235-244.
                • Silja Wessler, et al. (2000) Helicobacter pylori activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors. Journal of Biological Chemistry 275, 3629-3636.